Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases

Cancer

Volumn 116, Issue 18, 2010, Pages 4238-4247

  Niwińska, Anna ^a   Murawska, Magdalena ^a   Pogoda, Katarzyna ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Brain metastases; Human epidermal growth factor receptor 2 (HER2) positive breast cancer; Systemic treatment; Triple negative breast cancer; Whole brain radiotherapy

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETOPOSIDE; FLUOROURACIL; FULVESTRANT; GOSERELIN; LAPATINIB; MEGESTROL ACETATE; NAVELBINE; PLATINUM; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ERBB2 PROTEIN, HUMAN;

ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; PRIORITY JOURNAL; SYSTEMIC THERAPY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; EVALUATION STUDY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; SKULL IRRADIATION;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CRANIAL IRRADIATION; FEMALE; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 77957346508     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25391     Document Type: Article

References (30)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608-3617.
2. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumabbased therapy for metastatic breast carcinoma. Cancer. 2003; 97:2972-2977.
3. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer. 1992;69:972-980.
4. Arnold SM, Patchell RA. Diagnosis and management of brain metastases. Hematol Oncol Clin North Am. 2001;15: 1085-1107.
5. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Wiener EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer. High incidence of central nervous system metastases. Cancer. 2008; 113:2638-2645.
6. Niwińska A, Murawska M, Pogoda K. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol. 2010;21:942-948.
7. Nam BK, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008;10:R20.
8. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751. (Pubitemid 27181303)
9. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
10. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650-655.
11. Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009;27:1168-1176.
12. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
13. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14:5158-5165.
14. Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys. 2009 Nov 23. [Epub ahead of print].
15. Rudnicka H, Niwińska A, Murawska M. Breast cancer leptomeningeal metastasis - the role of multimodality treatment. J Neurooncol. 2007;84:57-62. (Pubitemid 47103444)
16. Metha MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:71-83.
17. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002; 20:3644-3650. (Pubitemid 34983224)
18. Cocconi G, Lottici R, Bisagni G, et al. Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest. 1990;8:327-334. (Pubitemid 20352764)
19. Fabi A, Vidiri A, Ferretti G, et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: another arrow at the bow? Cancer Invest. 2006;24:466-468.
20. Hikino H, Yamada T, Johbara K, Obayashi N, Ozaki N. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast. 2006;15:97-99. (Pubitemid 43210556)
21. Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24:421-424. (Pubitemid 32730746)
22. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85:223-227. (Pubitemid 47629405)
23. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107:1348-1354. (Pubitemid 44452785)
24. Omuro AM, Raizer JJ, Demopoulos A, Malkin MG, Abrey LE. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol. 2006;78:277-280. (Pubitemid 44018822)
25. Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol. 2008;31:250-254.
26. Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER2-positive metastatic breast cancer patients with trastuzumab: incidence, survival and risk factors. Oncologist. 2007;12:766-773.
27. Bartsch R, Rottenfusser A, Wenzel C, et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J Neurooncol. 2007;85: 311-317.
28. Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008;112: 2359-2367.
29. Dawood S, Broglio K, Esteva FJ, et al. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol. 2008;19:1242-1248.
30. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26:1993-1999.